glp 1 agonists canada View of Current Utilization Patterns of Glucagon-Like Peptide-1 Receptor Market Intelligence Report: Antidiabetic Drugs,
Description
doi: 10.1111/dom.12596 94 GlaesnerWVickAMMillicanREllisBTschangSHTianYet al
Diabetes Research And Clinical Practice, 172 ,
Many GLP-1 medications currently on the market require subcutaneous injection, which may be a barrier to treatment for some individuals who prefer oral medications or have a fear of needles
Both hormones matter, but GLP-1 is likely the primary driver with GIP providing substantial enhancement
(2022) Structural determinants of dual incretin receptor agonism by tirzepatide
